Anxiety is a common mental health condition that affects approximately 6.6% of the population in England each week, along with one in six adults experiencing or being identified as having a common mental health condition per week,
. Data suggest that women are almost twice as likely to be diagnosed with anxiety compared with men; however, the reason for this is unclear,
. Although a large number of people are affected by mental health conditions (e.g. anxiety or depression), only 39% of adults aged 16–74 years are accessing treatment for them
Mental health conditions typically worsen over time and can negatively impact on social activities, relationships, career performance, academic work and general quality of life
. As such, patients that present with conditions, such as generalised anxiety disorder (GAD), are frequently seen in the community, with pharmacists having the opportunity to significantly impact on the patient’s quality of life by providing information on the treatment options that are available
. While occasional anxiety is a normal aspect of day-to-day life, persistent symptoms can indicate the possible presence of an anxiety disorder, which can often be debilitating. Anxiety has also been known to precipitate physiological responses, such as tachycardia and hyperhidrosis
. ’Functional impairment’ is a term that is often used to describe the degree to which an illness can limit a person’s ability to carry out some of their normal daily tasks; anxiety can affect this to differing degrees
There are multiple factors that could predispose or potentially encourage the manifestation of anxiety, which are often attributable to a combination of genetic and environmental factors
. In addition, studies suggest that alcohol and illicit drug use, particularly the use of stimulants and hallucinogens, are associated with higher rates of incidence,
. Instances of childhood abuse and sexual abuse are also identified as potential causative factors for anxiety and depression
. However, there is a broad range of patients affected by anxiety, for whom there is often an unknown cause.
Types of anxiety
Anxiety disorder is an inclusive term for several disorders, including:
- Panic disorder;
- Selective mutism;
- Separation anxiety;
- Social anxiety disorder
The most common types of anxiety disorder include:
- Social anxiety disorder — this is considered to be the most common form of anxiety; in up to 50% of cases, it is present in individuals by age 11 years
. Symptoms include a persistent fear of social performance, panic attacks and a large fear of humiliating oneself in public
- Phobic disorder — this broadly refers to a fear of places, situations, objects and animals. For example, agoraphobia is often considered to be simply a fear of open spaces, but it is far more serious and can include a fear of being in a place that individuals will find difficult to escape from or receive aid if things go wrong
Avoidance behaviour is common to both social anxiety disorder and phobic disorder, with patients actively trying not to encounter the feared stimulus (e.g. avoiding going outside, such as in cases of agoraphobia),,
. This behaviour can hugely impact on a patient’s ability to maintain functional capacity.
Symptoms and diagnosis
Symptoms may involve feelings of restlessness, palpitations, problems with concentrating, uncontrollable worry, sleep disturbances and general irritability
Diagnosis of anxiety would initially be made by a GP following a comprehensive review of the following:
- Symptomatic presentation of the patient;
- Frequency of symptoms;
- Degree of severity of distress;
- Functional impairment.
History of substance misuse, comorbidities and past medical history should be considered as part of a holistic approach to diagnosis
In addition, differential diagnoses must be considered before a formal diagnosis is made. Anaemia and hyperthyroidism are two conditions that must be ruled out and/or treated as they can both manifest symptoms of anxiety disorders,
. Blood analysis and further tests may be necessary to ensure a correct diagnosis is made,
. As stated by the National Institute for Health and Care Excellence (NICE), diagnostic tools, such as the Diagnostic and Statistical Manual of Mental Disorders, can be utilised for anxiety disorders
. The criteria include a minimum of six months of incessant and uncontrollable worries, disproportionate to actual risk, and three of the following symptoms:
- Being easily fatigued;
- Muscle tension;
- Poor concentration;
- Sleep disturbance
The ‘International Classification of Diseases, 10th revision’, a disease classification tool, offers a similar criteria
. There are also other resources available to healthcare professionals to work through with patients, such as the GAD-7 questionnaire for anxiety and the personal health questionnaire-9 (PHQ-9) for depression
. Questions typically ask how frequently certain symptoms have occurred in the preceding two weeks. Both GAD-7 and PHQ-9 allow assessors to distinguish between anxiety and depression, and provide an indication as to the severity of presentation, which can guide therapy. These are typically asked by a GP during an initial consultation with the patient and may include questions such as: ‘Over the past two weeks, how often have you been bothered by feeling nervous, anxious or on edge?’
The GAD-7 questionnaire can also be used as a tool to determine the severity of its presentation, with scores of 5 and above, 10 and above, and 15 and above (out of a possible 21) referring to mild, moderate and severe anxiety, respectively
. Higher scores are strongly associated with functional impairment, although individual characteristics of presentation will affect how the patient is treated.
For patients with mild anxiety, pharmacotherapy is not recommended. However, as per NICE guidelines, pharmacological treatment is recommended where significant functional impairment exists
. First-line drug treatment involves selective serotonin reuptake inhibitors (SSRIs; e.g. sertraline or fluoxetine)
SSRIs are widely used for GAD and are often well tolerated. In addition, they are considered to be safer in overdose than most other similarly indicated medicines, because they carry a lower risk of cardiac conduction abnormalities and seizures,,
. Selective serotonin–noradrenaline reuptake inhibitors (SNRIs; e.g. duloxetine and mirtazapine) are a suitable alternative; pregabalin is a tertiary option if the others are unsuitable or poorly tolerated
It is important to manage the patients’ expectations with pharmacological therapies. Providing a clear message that it could take between four and six weeks before the patient notices a benefit from their medicine is essential, as this will help ensure that they take their medication as directed. Patients should also be made aware of side effects and the withdrawal process (e.g. associated side effects) prior to commencing therapy
Common side effects of SSRIs include abnormal appetite, arrhythmias, impaired concentration, confusion, gastrointestinal discomfort and sleep disorders
. The incidence of side effects is reported to be highest within the first two weeks of starting treatment
. Although most common side effects tend to improve over time, sexual dysfunction can persist
. There is an increased risk with SSRIs in certain patient groups (e.g. young adults, children and patients with a previous history of suicidal behaviour) of suicidal ideation and self-harm; therefore, initiation of SSRIs must be reviewed weekly in those under aged under 30 years for the first four weeks of treatment. If the risk of recurrent suicidal behaviour is a concern, the healthcare professional may want to seek advice from the local crisis or home-based treatment team; SSRIs generally have a better safety profile than other drugs used for anxiety, but may require frequent monitoring in this case,
SSRIs are one of several classes of medicines that pose a risk for long QT syndrome, which occurs as a result of a prolonged QT interval on the electrocardiogram measurements of the heart. This can lead to torsades de pointes (a specific type of abnormal heart rhythm) and possible sudden cardiac death
It is important that SSRIs are withdrawn slowly to minimise the occurrence of SSRI discontinuation syndrome — an abrupt cessation of treatment that can cause a combination of psychological and physiological symptoms; the most common including nausea, dizziness, headache and lethargy
. Tapering drug doses slowly over several weeks will mitigate the effects of the withdrawal and minimise unnecessary re-initiation of the SSRI
Considerations for selective serotonin reuptake inhibitors and selective serotonin–noradrenaline reuptake inhibitors
Serotonin syndrome is a serious side effect that can occur with the use of SSRIs and SNRIs. It occurs as a result of overactivation of the 5-HT1A and 5-HT2A receptors, precipitated by serotonergic drug use
. Symptoms typically range from confusion and agitation to more serious symptoms, such as seizures, arrhythmias and loss of consciousness
. The risk of the syndrome is higher if patients are taking other medicines that can increase serotonin levels in the brain, such as tramadol and metoclopramide. Taking 5-HT1F agonists, which include sumatriptan, or a combination of medicines with the same effect, can also increase risk
If a decision is made to initiate an SSRI, despite the associated risk, patients should be provided with suitable information concerning the syndrome, which can be found on or printed from the NHS website
. If a patient experiences symptoms of serotonin sydrome, they should be advised to contact their GP surgery immediately. If this is unavailable, they should call NHS 111 for advice.
Alongside serotonin syndrome, SSRIs have been known to contribute to inappropriate antidiuretic hormone secretion, which is related to hyponatremia and has symptoms including headache, insomnia, nervousness and agitation
Patients with anxiety disorders should be monitored as frequently as the severity of the disorder demands, which is essential to protect patients and improve their quality of life. Guidance from the British National Formulary states that patients being initiated on an SSRI should be reviewed every one to two weeks after initiation, with response being assessed at four weeks to determine whether continuation of the drug is suitable
. NICE guidelines expand on this by encouraging three-monthly reviews of drug therapy to assess clinical effectiveness
Patients should be advised to minimise alcohol intake and make time for activities they find relaxing. They should also be encouraged to exercise every day, aiming to do 150 minutes of moderate-intensity exercise (e.g. walking or cycling) per week as exercising has been shown to improve mental health,
. A study has demonstrated that those who exercise had 43.2% fewer days of poor mental health, with team sports having the largest association with reduction in mental health burden
Cognitive behavioural therapy (CBT) is a common psychological treatment used for those with anxiety. This therapy aims to transform negative thinking into more structured thought patterns, which then assist the patient in making changes to their thought processes to encourage positive thinking. CBT is suitable for patients that present with ongoing anxiety and does not look at patient history
. This type of treatment may be useful for patients with mild anxiety, as an addition to medicine or for those who do not wish to take medicine. It can be conducted individually or as part of a group.
Guided self-help — a process by which a patient is able to work through a course with the support of a trained therapist — and counselling are other treatments available through the NHS that may benefit patients with mild anxiety or as an adjunct to prescription medicines
Specialist referral and suicide risk
Specialist referral should be considered if patients:
- Have not responded to initial therapy;
- Have comorbidities, such as alcohol or substance misuse;
- Are at significant suicide risk.
Healthcare professionals should always assess suicide risk by discussing the patients’ feelings about self-harm openly and considering other contributing factors, such as the use of prescribed or illicit drugs. Healthcare professionals must take opportunities to make interventions — for example, referring patients for urgent mental health assessment or in the case of serious concerns, calling emergency services
In the UK, area-specific community programmes and the charity Anxiety UK can provide patients with further advice on managing their anxiety. However, many primary care networks are now recruiting social prescribers, who will have the ability to direct patients to attend local groups that are more suited to individual needs. Community pharmacists are also likely to be aware of local support networks.
Case study 1: a woman taking interacting medicines
Joanne*, a woman aged 65 years, approaches the pharmacy counter. She is concerned about heart palpitations she has been experiencing recently.
After inviting Joanne into the consultation room, you ask her if she is taking any medicines. She says that she is taking amitriptyline for the pain in her legs. She has also recently started taking a new medicine and states that she is on other medicines, but cannot recall the names. You ask for permission to view her summary care record and note that there is furosemide on her list of medicines. She was started on citalopram two weeks prior and was prescribed a seven-day course of clarithromycin three days ago.
You are concerned that Joanne is experiencing long QT syndrome, since the selective serotonin reuptake inhibitor (SSRI) citalopram is a risk factor for QT prolongation — as are the tricyclic antidepressant amitriptyline and the antibiotic clarithromycin,,
. In addition, furosemide can also precipitate hypokalaemia, which has been known to affect the QT interval
Advice and recommendations
You advise Joanne to stop taking the citalopram that has been prescribed to her until she can see a GP, which is a matter of urgency, as you believe it could be related to the medicines she is taking. You advise that she should try and get a same-day appointment if possible. The GP will likely request an electrocardiogram and stop the SSRI if results demonstrate long QT syndrome.
Case study 2: a man with concerns about his medicine
Gareth*, an investment banker aged 52 years, attends the pharmacy and asks to purchase sildenafil over the counter, owing to his erectile dysfunction. He is referred to you and you sit with him in the consultation room.
During the consultation, you begin to ask questions about his history and whether the erectile dysfunction is a new condition that he is experiencing. He states that he has been worried about it for the last couple of months. You then discuss his lifestyle and ask him questions about his medicines, in which he states he started taking a new medicine, fluoxetine, several months ago. He has been under significant stress at his workplace and was started on fluoxetine owing to his anxiety.
You consider the following:
- The erectile dysfunction that Gareth is experiencing could be related to the stress he is experiencing as part of his work;
- The possibility there could be an underlying reason for the problem related to his general health;
- That the prescribed fluoxetine may be causing his erectile dysfunction because this is a side effect of selective serotonin reuptake inhibitors
Advice and recommendations
You explain your rationale with Gareth and indicate that you do not think it is appropriate to sell him sildenafil now. You suggest he goes back to his GP to discuss the symptoms that he has been having. The GP may decide to try an alternative medicine, but, given that he has been taking the fluoxetine for a few months, he should not discontinue it until advised to do so by his GP. You explain that if his GP advises him to stop the medicine, there will be a specific withdrawal process to minimise the side effects and that you would be able to advise him on this.
Case study 3: a man who is displaying symptoms of moderate anxiety
Anton*, a university graduate aged 21 years, attends the pharmacy and asks to speak to the pharmacist in private. He states he is worried about heart palpitations that he has been experiencing. He is visibly sweating and looks on edge.
You invite Anton into the consultation room and ask him about his symptoms. He states that he has started a new job and that the palpitations start when he is feeling anxious. His symptoms are occurring most days of the week and he says it makes him “feel on edge”. He adds that he does not want to socialise with his co-workers. It is starting to affect his sleep and he does not know what to do. He also states that he has occasional pain in his chest.
Anton is demonstrating symptoms of moderate anxiety, given his desire to avoid socialising, and has a degree of functional impairment. However, as he has potential cardiac symptoms, these issues could be related to another condition.
When questioned, he confirms he has no other problems with his health, but you feel the patient needs further investigation — for example, an electrocardiogram test to measure the electrical activity of his heart to rule out underlying cardiac problems. His presentation concerns you and you feel he needs to see a doctor today to assess the differential diagnosis, as you are worried about his chest pain and palpitations.
Advice and recommendations
You encourage Anton by saying that it is great that he felt he could talk to a pharmacist about this, but explain that he would benefit from a consultation with a GP. You explain that his symptoms could be related to anxiety and that you think he may need something to help him manage. He agrees to let you contact his local practice. As you have a good relationship with the practice, you manage to secure an appointment for him to see a GP that day. If a GP appointment had been unavailable, you could have telephoned NHS 111 for Anton to seek access to support.
*All cases are fictional
 Fineberg NA, Haddad PM, Carpenter L et al. The size, burden and cost of disorders of the brain in the UK. J Psychopharmacol 2013;27(9):761–770. doi: 10.1177/0269881113495118
 Anxiety UK. Frequently asked questions. 2018. Available at: https://www.anxietyuk.org.uk/get-help/anxiety-information/frequently-asked-questions/ (accessed May 2020)
 No Panic. Anxiety statistics. 2018. Available at: https://nopanic.org.uk/anxiety-statistics/ (accessed May 2020)
 NHS England. Women are more likely to suffer from anxiety than men. 2016. Available at: https://www.nhs.uk/news/mental-health/women-are-more-likely-to-suffer-from-anxiety-than-men/ (accessed May 2020)
 NHS Digital. Adult psychiatric morbidity survey: Survey of mental health and wellbeing, England 2014. 2014. Available at: https://digital.nhs.uk/data-and-information/publications/statistical/adult-psychiatric-morbidity-survey/adult-psychiatric-morbidity-survey-survey-of-mental-health-and-wellbeing-england-2014 (accessed May 2020)
 National Institute of Mental Health. Anxiety disorders. 2018. Available at: https://www.nimh.nih.gov/health/topics/anxiety-disorders/index.shtml (accessed May 2020)
 Braga SFF, Clark KJ & Shirer AE. US Pharm. An overview of generalized anxiety disorder for the community pharmacist. 2019. Available at: https://www.uspharmacist.com/article/an-overview-of-generalized-anxiety-disorder-for-the-community-pharmacist (accessed May 2020)
 McLeod DR, Hoehn-Daric R & Stefan RL. Somatic symptoms of anxiety: comparison of self-report and physiological measures. Biol Psychiatry 1986;21(3):301–310. doi: 10.1016/0006-3223(86)90051-x
 UstÃ¼n B & Kennedy C. What is “functional impairment”? Disentangling disability from clinical significance. World Psychiatry 2009;8(2):82–85. doi: 10.1002/j.2051-5545.2009.tb00219.x
 Durbano F. A Fresh Look at Anxiety Disorders. InTech: Croatia; 2015
 Schuckit MA & Hesselbrock V. Alcohol dependence and anxiety disorders. Focus 2004;2(3):440–453. doi: 10.1176/foc.2.3.440
 Sareen J, Chartier M, Paulus MP & Stein MB. Illicit drug use and anxiety disorders: findings from two community surveys. Psychiatry Res 2006;142(1):11–17. doi: 10.1016/j.psychres.2006.01.009
 Mancini C, Van Ameringen M & MacMillan H. Relationship of childhood sexual and physical abuse to anxiety disorders. J Nerv Men Dis 1995;183(5):309–314. doi: 10.1097/00005053-199505000-00006
 Anxiety and Depression Association of America. Understanding the facts of anxiety disorders and depression is the first step. 2020. Available at: https://adaa.org/understanding-anxiety (accessed May 2020)
 Stein MB & Stein DJ. Social anxiety disorder. Lancet 2008;371(9618):1115–1125. doi: 10.1016/S0140-6736(08)60488-2
 Marks I. Fears, Phobias and Rituals: Panic, Anxiety and Their Disorders. Oxford University Press: New York; 1987.
 NHS. Phobias. 2018. Available at: https://www.nhs.uk/conditions/phobias/ (accessed May 2020)
 Hofmann S & DiBartolo P. Social Anxiety: Clinical, developmental and social perspectives. 3rd edn. Academic Press: San Diego; 2014.
 Marks I. Fears and Phobias. Academic Press: New York; 1969.
 National Institute for Health and Care Excellence. Generalised anxiety disorder and panic disorder in adults: management. Clinical guideline [CG113]. 2011. Available at: https://www.nice.org.uk/guidance/cg113/resources/generalised-anxiety-disorder-and-panic-disorder-in-adults-management-35109387756997 (accessed May 2020)
 National Institute for Health and Care Excellence. NICE Pathways. Generalised anxiety disorder. 2019. Available at: https://pathways.nice.org.uk/pathways/generalised-anxiety-disorder (accessed May 2020)
 British Thyroid Foundation. Hyperthyroidism. 2018. Available at: https://www.btf-thyroid.org/hyperthyroidism-leaflet (accessed May 2020)
 NHS. Generalised anxiety disorder in adults. 2018. Available at: https://www.nhs.uk/conditions/generalised-anxiety-disorder/ (accessed May 2020)
 National Institute for Health and Care Excellence. Clinical knowledge summaries. Generalized anxiety disorder. 2017. Available at: https://cks.nice.org.uk/generalized-anxiety-disorder (accessed May 2020)
 Spitzer RL, Kroenke K, Williams JB & Lowe B. A brief measure for assessing generalized anxiety disorder. Arch Intern Med. 2006;166:1092–1097. doi: 10.1001/archinte.166.10.1092
 National Institute for Health and Care Excellence. Generalized anxiety disorder. Scenario: management of a person with generalized anxiety. 2017. Available at: https://cks.nice.org.uk/generalized-anxiety-disorder#!scenario (accessed May 2020)
 British National Formulary. 2020. Available at: https://bnf.nice.org.uk/ (accessed May 2020)
 Ferguson JM. SSRI Antidepressant medications: adverse effects and tolerability. Prim Care Companion J Clinl Psychiatry 2001;3(1):22–27. doi: 10.4088/pcc.v03n0105
 Yekehtaz H, Farokhnia M & Akhondzadeh S. Cardiovascular considerations in antidepressant therapy. J Tehran Heart Cent 2013;8(4):169–176. PMID: 260058484
 Warden D, Trivedi MH, Wisniewski SR et al. Early adverse events and attrition in selective serotonin reuptake inhibitor treatment: a suicide assessment methodology study report. J Clin Psychopharmacology 2010;30(3):259–266. doi: 10.1097/JCP.0b013e3181dbfd04
 NHS. Antidepressants. 2018. Available at: https://www.nhs.uk/conditions/antidepressants/ (accessed May 2020)
 National Institute for Health and Care Excellence. Antidepressant drugs. 2020. Available at: https://bnf.nice.org.uk/treatment-summary/antidepressant-drugs.html
 Funk KA & Bostwick JR. A comparison of the risk of QT prolongation among SSRIs. Ann Pharmacother 2013;47(10): 1330-1341. doi: 10.1177/1060028013501994
 Kannankeril PJ & Roden DM. Drug-induced long QT and torsade de pointes: recent advances. Curr Opin Cardio 2007;22(1):39–43. doi: 10.1097/HCO.0b013e32801129eb
 Yap YG & Camm AJ. Drug induced QT prolongation and torsades de pointes. Heart 2003;89(11):1363–1372. doi: 10.1136/heart.89.11.1363
 Haddad P. The SSRI discontinuation syndrome. J Psychopharmacol 1998;12(3): 305–313. doi: 10.1177/026988119801200311
 Horowitz M & Taylor D. Tapering of SSRI treatment to mitigate withdrawal symptoms. Lancet Psychiatry. 2019;6:538–546. doi: 10.1016/S2215-0366(19)30032-X
 Volpi-Abadie J, Kaye AM & Kaye AD. Serotonin Syndrome. Ochsner J 2013;13(4):533–540. PMID: 24358002
 Specialist Pharmacy Service. What is serotonin syndrome and which medicines cause it? 2020. Available at: https://www.sps.nhs.uk/articles/what-is-serotonin-syndrome-and-which-medicines-cause-it-2/ (accessed May 2020)
 Kirpekar VC & Joshi PP. Syndrome of inappropriate ADH secretion (SIADH) associated with citalopram use. Indian J Psychiatry 2005;47(2):119–120. doi: 10.4103/0019-5545.55960
 NHS. Get fit for free. 2019. Available at: https://www.nhs.uk/live-well/exercise/free-fitness-ideas/ (accessed May 2020)
 Anxiety UK. Physical Exercise & Anxiety. 2018. Available at: https://www.anxietyuk.org.uk/get-help/anxiety-information/physical-exercise-anxiety/ (accessed May 2020)
 Chekroud SG, Gueorguieve R, Zheutlin AB et al. Association between physical exercise and mental health in 1.2 million individuals in the USA between 2011 and 2015: a cross-sectional study. Lancet Psychiatry 2018;5(9):739–746. doi: 10.1016/S2215-0366(18)30227-X
 NHS. Types of talking therapies. 2018. Available at: https://www.nhs.uk/conditions/stress-anxiety-depression/types-of-therapy/ (accessed May 2020)
 Vieweg WV & Wood MA. Tricyclic Antidepressants, QT interval prolongation and torsade de pointes. Psychosomatics 2004;45(5):371–377.doi: 10.1176/appi.psy.45.5.371
 Kamochi H, Nii T, Eguchi K et al. Clarithromycin associated with torsades de pointes. Jpn Circ J 1999;63:421–422. doi: 10.1253/jcj.63.421
 Snitker S, Doerfier RM, Soliman EZ et al. Association of QT-prolonging medication use in CKD with electrocardiographic manifestations. Clin J Am Soc Nephrol 2017;12(9):1409–1417. doi: 10.2215/CJN.12991216
 Montejo-Gonzalez AL, Llorca G, Izguierdo JA et al. SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline and fluvoxamine in a prospective, multicentre and descriptive clinical study of 344 patients. J Sex Marital Ther 1997;23(3):176–194. doi: 10.1080/00926239708403923